We leverage our proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. Drug Development Services: We work with leading biopharmaceutical companies to unlock response dynamics (ex vivo efficacy) for their investigational cancer drug candidates in preclinical testing and subsequent clinical trials. Clinical Testing Services (CLIA-certified laboratory): In 2019 we published of our assay’s analytical validation and clinical evidence of its predictive performance. Currently we are further validating drug response-predictive clinical assays as well as undertaking investigator-initiated studies in ovarian cancer, high-grade glioma, breast cancer and rare tumors.